Literature DB >> 2468086

Comparison of the primary structure of the 25 kDa ookinete surface antigens of Plasmodium falciparum and Plasmodium gallinaceum reveal six conserved regions.

D C Kaslow1, C Syin, T F McCutchan, L H Miller.   

Abstract

The gene encoding the 25 kDa ookinete surface antigen (Pgs25) of Plasmodium gallinaceum has been cloned using an oligonucleotide probe directed against one of the EGF-like domains of the P. falciparum 25 kDa ookinete surface antigen (Pfs25). The Pgs25 gene codes for a polypeptide of 215 amino acids, two amino residues less than Pfs25. The deduced amino acid sequence contains a putative signal sequence at the amino-terminus, four tandemly repeated EGF-like domains, and a hydrophobic region at the carboxyl-terminus. By comparing Pgs25 with Pfs25, six conserved regions, consisting of six or more amino acid residues, have been identified. Most of the conserved regions are outside EGF-like core consensus sequences. The most striking conservation is the spacing of the cysteines.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2468086     DOI: 10.1016/0166-6851(89)90090-x

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  14 in total

1.  P25 and P28 proteins of the malaria ookinete surface have multiple and partially redundant functions.

Authors:  A M Tomas; G Margos; G Dimopoulos; L H van Lin; T F de Koning-Ward; R Sinha; P Lupetti; A L Beetsma; M C Rodriguez; M Karras; A Hager; J Mendoza; G A Butcher; F Kafatos; C J Janse; A P Waters; R E Sinden
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

Review 2.  Plasmodium p25 and p28 surface proteins: potential transmission-blocking vaccines.

Authors:  Ajay K Saxena; Yimin Wu; David N Garboczi
Journal:  Eukaryot Cell       Date:  2007-06-08

3.  Isolation and functional characterization of two distinct sexual-stage-specific promoters of the human malaria parasite Plasmodium falciparum.

Authors:  K J Dechering; A M Kaan; W Mbacham; D F Wirth; W Eling; R N Konings; H G Stunnenberg
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

4.  A novel malaria protein, Pfs28, and Pfs25 are genetically linked and synergistic as falciparum malaria transmission-blocking vaccines.

Authors:  P E Duffy; D C Kaslow
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

5.  Two antigens on zygotes and ookinetes of Plasmodium yoelii and Plasmodium berghei that are distinct targets of transmission-blocking immunity.

Authors:  T Tsuboi; Y M Cao; Y Hitsumoto; T Yanagi; H Kanbara; M Torii
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

6.  Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes.

Authors:  H Hisaeda; A W Stowers; T Tsuboi; W E Collins; J S Sattabongkot; N Suwanabun; M Torii; D C Kaslow
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

7.  Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates.

Authors:  T Tsuboi; D C Kaslow; M M Gozar; M Tachibana; Y M Cao; M Torii
Journal:  Mol Med       Date:  1998-12       Impact factor: 6.354

8.  Serum antibody immunoglobulin G of mice convalescent from Plasmodium yoelii infection inhibits growth of Plasmodium falciparum in vitro: blood stage antigens of P. falciparum involved in interspecies cross-reactive inhibition of parasite growth.

Authors:  P Ray; N Sahoo; B Singh; F A Kironde
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

9.  Plasmodium falciparum ookinetes migrate intercellularly through Anopheles stephensi midgut epithelium.

Authors:  J F Meis; G Pool; G J van Gemert; A H Lensen; T Ponnudurai; J H Meuwissen
Journal:  Parasitol Res       Date:  1989       Impact factor: 2.289

10.  Pgs28 belongs to a family of epidermal growth factor-like antigens that are targets of malaria transmission-blocking antibodies.

Authors:  P E Duffy; P Pimenta; D C Kaslow
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.